Carole Philipponnet

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Open lung biopsy in nonresolving ARDS frequently identifies diffuse alveolar damage regardless of the severity stage and may have implications for patient management

Claude Guérin, Frédérique Bayle, Véronique Leray et al. · Intensive Care Medicine · 2014 · 94 citations · Full text

Alveolar Damage Regardless, Advanced Lung Disease, Medicine +8

Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes

Cyril Garrouste, Guillaume Canaud, M. Büchler et al. · Transplantation · 2016 · 72 citations

Bile Cast Nephropathy Caused by Obstructive Cholestasis

Julien Aniort, Anaïs Poyet, Jean-Louis Kémény et al. · American Journal of Kidney Diseases · 2016 · 43 citations

Urology, Biliary Tract, Primary Sclerosing Cholangitis +6